Since 2017, as required by the U.S. Food and Drug Administration, the COPD and asthma drug montelukast has carried a warning of its adverse side effects that include agitation, anxiousness, aggression, dream abnormalities, depression, and insomnia, reports HealthDay. Now, a recent review, published in the journal Pharmacology Research and Perspectives, shows it drastically increases the chance of neuropsychiatric problems like aggressive behavior, nightmares, and depression.By analyzing information from two large databases, global database Vigibase, which is maintained by the World Health Organization and the Netherlands Pharmacovigilance Centre Lareb, researchers found that children who were taking montelukast:

the odds of depression were nearly seven times higher
the odds of aggressive behavior were 30 times higher
the odds of nightmares were 22 times higher

Prev1 of 2
Continue Reading on Next Page


Share.

Leave A Reply